The companion diagnostics field got off to an auspicious start in January 2017 when Singulex Inc., the next-generation immunodiagnostics company based in Alameda, CA, announced it was entering a strategic alliance with Qiagen NV, the European diagnostics specialist with headquarters in Hilden, Germany, for the development of companion diagnostics. The deal gives Qiagen access to Singulex’s Single Molecule Counting (SMC) immunodiagnostic technology, thereby strengthening its existing immunoassay capabilities, as well as to Singulex’s CLIA-licensed laboratory in California.
Companion diagnostics are an essential component of precision medicine, the doctrine of delivering the right medicine to the right patient...
